Smith & Nephew Reports Strong Q3 2025 Growth and Raises Cash Flow Guidance

Smith & Nephew Snats ( (SNN) ) has provided an update.

Smith & Nephew reported a 5.0% underlying revenue growth in the third quarter of 2025, with a total revenue of $1,501 million, driven by strong performance in orthopaedics, sports medicine, and advanced wound management. The company has completed a $500 million share buyback and raised its free cash flow guidance to $750 million, reflecting robust cash generation and operational efficiency. New product launches, such as the CORIOGRAPH Pre-Op Planning and Modeling Services and the CENTRIO PRP System, have contributed significantly to revenue growth, supporting the company’s strategic goals and enhancing its market position.

The most recent analyst rating on (SNN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.

Spark’s Take on SNN Stock

According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.

Smith & Nephew Snats’ strong financial performance and positive earnings call outlook are the primary drivers of its stock score. While technical indicators show mixed momentum, and valuation suggests the stock may be expensive, the company’s robust cash flow and strategic initiatives support a positive outlook. Challenges in emerging markets and potential tariff impacts are notable risks.

To see Spark’s full report on SNN stock, click here.

More about Smith & Nephew Snats

Smith & Nephew is a global medical technology company operating in the healthcare industry. It specializes in orthopaedics, sports medicine, ENT, and advanced wound management, focusing on innovative solutions for medical professionals and patients worldwide.

Average Trading Volume: 664,265

Technical Sentiment Signal: Buy

Current Market Cap: $15.7B

For detailed information about SNN stock, go to TipRanks’ Stock Analysis page.